CAVALLETTO, LUISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.425
EU - Europa 721
AS - Asia 374
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
SA - Sud America 2
Totale 5.526
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.422
CN - Cina 352
IT - Italia 213
FI - Finlandia 150
DE - Germania 117
SE - Svezia 94
UA - Ucraina 67
GB - Regno Unito 40
IE - Irlanda 18
IN - India 14
AL - Albania 6
JP - Giappone 5
FR - Francia 4
RO - Romania 4
CA - Canada 3
NL - Olanda 3
AU - Australia 2
ES - Italia 2
EU - Europa 2
SI - Slovenia 2
TR - Turchia 2
DK - Danimarca 1
PY - Paraguay 1
SG - Singapore 1
UY - Uruguay 1
Totale 5.526
Salva come PNG Salva come JPEG
Città #
Fairfield 650
Jacksonville 441
Houston 410
Chandler 385
Woodbridge 379
Wilmington 282
Ashburn 276
Cambridge 254
Ann Arbor 211
Seattle 196
Princeton 152
Medford 82
San Diego 79
Nanjing 73
Beijing 56
Helsinki 55
Boardman 53
Des Moines 48
Roxbury 35
Padova 25
Nanchang 24
Guangzhou 23
Hebei 23
New York 22
Shenyang 21
Dublin 18
Hefei 17
Jinan 16
Changsha 15
Milan 15
Dearborn 13
Jiaxing 13
Norwalk 11
Tianjin 11
London 10
Pune 10
Redwood City 10
Kharkiv 8
Naples 8
Zhengzhou 8
Kunming 7
Cagliari 6
Ningbo 6
Bari 5
Hirakata 5
Ogden 5
Rome 5
Aci Catena 4
Bologna 4
Borås 4
Brugherio 4
Chiswick 4
Rockville 4
Venice 4
Ancona 3
Auburn Hills 3
Bergamo 3
Detroit 3
Fremont 3
Hangzhou 3
Kilburn 3
Legnaro 3
Moretta 3
Ponzano Veneto 3
Potenza 3
San Jose 3
Tirana 3
Tortorici 3
Washington 3
Acton 2
Brescia 2
Carbonera 2
Catania 2
Conversano 2
Cornedo Vicentino 2
Fuzhou 2
Hanover 2
Harbin 2
Horia 2
Majadahonda 2
Mascalucia 2
Messina 2
Mestre 2
Orange 2
Peshkopi 2
Recco 2
Rimini 2
Rovigo 2
Shanghai 2
Teglio Veneto 2
Trieste 2
Turin 2
Wuhan 2
Yellow Springs 2
Yenibosna 2
Acquedolci 1
Andover 1
Asunción 1
Atlanta 1
Baotou 1
Totale 4.607
Salva come PNG Salva come JPEG
Nome #
LA CURA DEL PAZIENTE CON EPATITE C: dall'epidemiologia alla buona pratica clinica attraverso metodologie sperimentali e di laboratorio. 202
Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study 135
SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection 109
Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. 109
Kinetic of virological response during PEG-IFNs in chronic hepatitis C. 102
Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma 102
SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection 102
Hepatitis C virus reinfection in liver transplant patients: evaluation of liver damage progression with echo-color doppler. 101
Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. 98
Hepatitis C Virus Reinfection in Liver Transplant Patients: Evaluation of Liver Damage Progression with Echo-Color Doppler 97
Squamous cell carcinoma antigen (SCCA) expression and CD27+ memory B lymphocytes in patients with chronic hepatitis C 96
Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. 92
Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. 91
Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease 91
HEART RATE VARIABILITY PARALLELS CHANGES IN PSYCHIATRIC SCALES IN INTERFERON-TREATED PATIENTS WITH CHRONIC HEPATITIS 88
Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population 85
Profiles of HCV core protein and viremia in chronic hepatitis C: Possible protective role of core antigen in liver damage 85
Cognitive effects of long-term interferon treatment for chronic viral hepatitis 84
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 84
PERFORMANCE OF TRANSIENT ELASTOGRAPHY AND NON INVASIVE MARKERS OF LIVER FIBROSIS IN PRIMARY BILIARY CIRRHOSIS 83
Therapy of hepatitis C: re-treatment with alpha interferon. 82
HEPATITIS C VIRUS SEROTYPES AND LIVER PATHOLOGY 81
PERFORMANCE OF TRANSIENT ELASTOGRAPHY AND NON INVASIVE MARKERS OF LIVER FIBROSIS IN PRIMARY BILIARY CIRRHOSIS 81
Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C 75
Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. 74
Human leucocyte interferon-alpha in the treatment of chronic hepatitis C 70
Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis 69
Validation of a new sonographic parameter (liver/kidney ratio of greys intensity of digital images) for diagnosis and quantification of liver steatosis 68
Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer 68
Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals 68
Monitoring SCCA-IgM complex predicts hcc development in cirrhotic patients 67
Alterazioni neurovascolari nell’epatite cronica C: uno studio caso-controllo 65
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 64
Epidemiological and clinical profile of HCV Chronic carriers in the area of northern Italy 60
RESPONSE TO RIBAVIRIN, TO INTERFERON AND TO A COMBINATION OF BOTH IN PATIENTS WITH CHRONIC HEPATITIS C AND ITS RELATION TO HCV GENOTYPES 59
TIMING AND DOSE EFFECT OF ALPHA-INTERFERON ON EARLY VIRAL KINETICS IN CHRONIC HEPATITIS C 57
Prognostic value of liver and spleen stiffness in patients with fontan associated liver disease (Fald): A case series with histopathologic comparison 57
COMPARISON OF THRICE WEEKLY VS DAILY HUMAN LEUCOCYTE INTERFERON-ALPHA THERAPY FOR CHRONIC HEPATITIS C. TVVH STUDY GROUP. 55
RESPONSE TO RIBAVIRIN, TO INTERFERON AND TO A COMBINATION OF BOTH IN PATIENTS WITH CHRONIC HEPATITIS C AND ITS RELATION TO HCV GENOTYPES 55
Heart rate variability parallels changes in psychiatric scales in interferon-treated patients with chronic hepatitis. 54
Non invasive diagnosis of liver fibrosis progression by a clinical and us-doppler predictive model during chronic HCV infection 54
Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. 54
Espressione della serpina SCCA in cellule mononucleate di sangue periferico in pazienti con infezione cronica da HCV 53
ESPRESSIONE DELLA SERPINA SCCA IN CELLULE MONONUCLEATE DI SANGUE PERIFERICO IN PAZIENTI CO INFEZIONE CRONICA DA HCV 52
CHRONIC HEPATITIS C WITHOUT ANTIBODY TO C-100 50
Comparison of thrice weekly vs daily human leucocyte interferon-alfa therapy for chronic hepatitis C. 49
HFE, TGF-BETA1 AND SQUAMOUS CELL CARCNOMA ANTIGEN-1 POLYMORPHISMS AND LIVER DISEASE STAGE IN CHRONIC HCV INFECTION 48
Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group. 47
NEUROCYTOKYNES CHANGES INDUCING PEG-INTERFERON-ALPHA DEPRESSION: A RATIONAL APPROACH TO INCREASE ADHERENCE OF THERAPY IN CHRONIC HEPATITIS C 45
Neurophysiological bases of IFN toxicity in the treatment of viral hepatitis: Psychiatric, cognitive changes and long-term electrophysiological correlates. 45
Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. 44
SCCA EXPRESSION IN PBMCs IN PATIENTS WITH CHRONIC HEPATITIS C 44
ESTIMATE OF FIBROSIS PROGRESSION DURING CHRONIC HEPATITIS C (CHC) IN NORTH-EAST ITALY 44
RETREATMENT OF CHRONIC HEPATITIS C (CHC) WITH SEQUENTIAL INTERFERON RIBAVIRIN COMBINATION (IFN-RIBA) THERAPY 44
THE EFFECT OF RE-TREATMENT WITH INTERFERON ALONE OR INTERFERN PLUS RIBAVIRIN ON HCV QUASISPECIES DIVERSIFICATION IN NONRESPONDER PATIENTS WITH CHRONIC HEPATITIS C 43
POLIMORFISMO DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) E PROGRESSIONE DELLA MALATTIA EPATICA NELL’INFEZIOE HCV 43
Serum miRNA are promising biomarkers for the detection of early hepatocellular carcinoma after treatment with direct-acting antivirals 43
Monitoring SCCA-IgM complex predicts liver disease progression in patients with chronic hepatitis and cirrhosis 43
Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma 43
Deregulation of Squamous Cell Carcinoma Antigen (SCCA) expression in B lymphocytes in patients with chronic hepatitis C 42
Terapia con Peg-interferone e ribavirina nell'epatite cronica C: costo-efficacia e farmacoutilizzazione nella comune pratica clinica 42
Changes in serum tryptophan during antiviral therapy with recombinant alfa-interferon in chronic hepatitis C 41
KINETIC OF VIROLOGICAL RESPONSE DURING PEG-IFNS IN CHRONIC HEPATITIS C. 41
Standard therapy for chronic HCV infection 41
Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group 40
Non-invasive diagnosis of liver fibrosis progression by a clinical and US-Doppler predictive model during chronic HCV infection 39
HEART RATE VARIABILITY PARALLELS CHANGES IN PSYCHIATRIC SCALES IN INTERFERON-TREATED PATIENTS WITH CHRONIC HEPATITIS. 38
DOWNREGULATION OF SURFACE SQUAMOUS CELL CARCINOMA ANTIGEN EXPRESSION AND CD27+ MOLECULE ON B LYMPHOCYTES IN PATIENTS WITH CHRONIC HEPATITIS C 38
The effect of interferon alpha and ribavirin combination therapy in naive patients with chronic hepatitis C. 37
SIGNIFICANCE OF HEPATITIS C VIRAEMIA IN ASYMPTOMATIC ANTI-HCV CARRIERS 37
The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C 37
METABOLIC SYNDROME INDUCES A MORE RAPID PROGRESSION OF FIBROSIS IN PRIMARY BILIARY CIRRHOSIS IN EARLY STAGE 36
Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alfa. 34
L'osservatorio epidemiologico e clinico sulle epatopatie croniche: uno strumento di politica sanitaria. 32
PEGYLATED ALPHA INTERFERONS (PEG-IFNs) PERIPHERAL NEUROTOXICITY: PROSPECTIVE STUDY IN CHRONIC HEPATITIS C. 32
ESPRESSIONE DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) E CELLULE B DELLA MEMORIA IN CORSO DI INFEZIONE DA VIRUS DELL’EPATITE C 32
PREDICTORS OF SVR IN PATIENTS WITH NAIVE CHRONIC HCV TREATED WITH PEG-IFN ALFA-2B VS. ALFA-2A + RIBAVIRIN: A HIERARCHICAL LINEAR REGRESSION ANALYSIS OF RETROSPECTIVE DATA FROM 6 CLINIC SITES. 30
Aspetti farmacoeconomici della terapia antivirale nell'epatite cronica C 30
Role of transient elastography to stage fontan-associated liver disease (Fald) in adults with single ventricle congenital heart disease correction 27
CLINICAL SIGNIFICANCE OF SERUM AND LIVER TISSUE SCCA IN CHRONIC HEPATITIS 26
Preventing interferon-induced depression in a sample of 44 chronic hepatitis C patients with risk factor for depression 26
Studio epidemiologico e prospettico delle epatopatie croniche: un progetto pilota nelle province di Padova e Venezia 26
LATE REACTIVATION OF CHRONIC HEPATITIS C AFTER SUSTAINED BIOCHEMICAL RESPONSE TO INTERFERON THERAPY 25
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. 25
THE LONG-TERM RESPONSE (LTR) TO INTERFERON-ALPHA (IFN-2a) IN CHRONIC HEPATITIS C IS INFLUENCED BY DOSE AND DURATION OF TREATMENT AND BY THE HCV SEROTYPE 23
DIFFERENT RATES OF HCV QUASISPECIES DIVERSIFICATION IN ASYMPTOMATIC CARRIERS AND IN PATIENTS WITH CHRONIC HEPATITIS 23
THE COMBINATION TREATMENT WITH RIBAVIRIN AND NATURAL INTERFERON- ALPHA MAY IMPROVE LONG TERM RESPONSE IN CHRONIC HEPATITIS C 23
The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group. 22
HEPATITIS C VIRUS (HCV) GENOTYPES AND CLINICAL COURSE OF ANTI-HCV POSITIVE CIRRHOSIS 21
PILOT STUDY ON THE EFFICACY OF INTRAVENOUS NATURAL BETA-INTERFERON THERAPY IN ITALIAN PATIENTS WITH CHRONIC HEPATITIS C AND RELATION TO THE HCV GENOTYPE 21
Novel pharmacogenetic test for management of antiviral therapy in patients with chronic hepatitis C 21
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of data from European Centers. 21
EVIDENCE THAT DOSE AND DURATION OF INTERFERON ALPHA (IFNa) THERAPY AFFECT LONG-TERM RESPONSE IN CHRONIC HEPATITIS C 20
IS SUSTAINED RESPONSE TO ?-INTERFERON IN CHRONIC HEPATITIS C REALLY MANTAINED AT LONG-TERM FOLLOW-UP ? 19
EFFICACIA DI DIFFERENTI TIPI DI DOSAGGI DI ALPHA-INTERFERONE IN SOGGETTI CON EPATITE CRONICA DI TIPO C 19
HEPATITIS C: DIAGNOSIS AND THERAPY 18
Antiviral therapy may change natural history of hepatitis C: clinical and histological modifications in a coohort of naive and treated patients 18
Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort 18
LA TERAPIA DELL’EPATITE CRONICA DA HCV 17
LONG-TERM VIROLOGICAL AND HISTOLOGICAL OUTCOME AFTER ALPHA-INTERFERON THERAPY IN CHRONIC HEPATITIS C 17
Totale 5.428
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.311
article - articoli 15.161
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 363
patent - brevetti 0
selected - selezionate 0
volume - volumi 758
Totale 35.593
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019407 0 0 0 0 0 0 0 0 0 89 167 151
2019/20201.165 210 37 12 65 101 89 146 130 112 137 47 79
2020/2021830 29 68 41 54 28 108 21 71 127 89 85 109
2021/20221.030 13 165 86 93 36 74 52 95 58 30 116 212
2022/20231.020 226 80 22 86 184 126 19 64 116 26 61 10
2023/2024306 16 53 45 33 37 55 29 16 11 11 0 0
Totale 5.555